Friday, March 05, 2010 8:30:27 PM
It’s raining good news for Incyte (INCY), which entered into a deal with Eli Lilly (LLY) regarding one of its pipeline candidates. The two companies have entered into a worldwide license and collaboration agreement related to the development and commercialization of Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and certain other follow on drugs for inflammatory and autoimmune diseases. INCB28050 is currently being studied in a phase II trial for the treatment of rheumatoid arthritis [RA].
As per the agreement, while Lilly will receive worldwide rights to the compound, Incyte has retained its co-development and co-promotion rights. Under the deal, Incyte will receive an initial payment of $90 million as well as another $665 million in the form of milestone payments. In addition, the company is also eligible to receive tiered, double-digit royalty payments on global sales of the drug on successful commercialization. Following the transaction, Lilly’s fourth quarter earnings will be impacted by 5 cents.
This is the second deal for Incyte within a span of one month. Back in November, Incyte entered into a collaboration and license agreement with Novartis (NVS) regarding two of its pipeline candidates -- INCB18424, an oral JAK1/JAK2 inhibitor and INCB28060, an oral cMET inhibitor. While the former is currently being studied in a phase III clinical trial for myelofibrosis [MF], the latter has yet to enter its phase I trial as a potential treatment for multiple cancers. Along with MF, INCB18424 is in phase II trial for patients with advanced polycythemia vera [PV] and essential thrombocythemia [ET].
We believe the recent deals with big pharma players prove the huge underlying potential of Incyte’s compounds. RA is an autoimmune disease affecting about 1% of the world's population. None of the current available treatment is curative and there is a significant unmet clinical need in this area.
Additionally, the MF drug holds immense potential as there are currently no approved specific therapies for MF, PV or ET which collectively constitute the major myloproliferative diseases. These disorders are estimated to affect more than 200,000 patients in the US and over twice that worldwide.
Incyte, being in a tight liquidity position, decided earlier this year to prioritize its pipeline development. Successful commercialization of these compounds with the aid of Incyte’s collaborating partners should enable Incyte to improve its financial position considerably. We have a Neutral recommendation on the stock.
Recent INCY News
- Incyte Completes Acquisition of Escient Pharmaceuticals • Business Wire • 05/30/2024 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/30/2024 07:12:24 PM
- Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings • Business Wire • 05/21/2024 05:15:00 PM
- Incyte to Present at Upcoming Investor Conference • Business Wire • 05/21/2024 12:00:00 PM
- Incyte präsentiert Daten aus seinem Onkologie-Portfolio beim Jahrestreffen 2024 der ASCO und beim EHA2024 Congress • Business Wire • 05/16/2024 01:45:00 AM
- Incyte présentera les données de son portefeuille d'oncologie lors de la réunion annuelle 2024 de l'ASCO et du congrès EHA2024 • Business Wire • 05/15/2024 03:44:00 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 05/15/2024 03:10:29 PM
- Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress • Business Wire • 05/14/2024 09:00:00 PM
- Producer Price Inflation Data May Weigh On Wall Street • IH Market News • 05/14/2024 01:05:30 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/13/2024 10:06:33 PM
- Dow Snaps Eight-Day Winning Streak After Lackluster Session • IH Market News • 05/13/2024 08:34:54 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 05/13/2024 03:19:07 PM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 05/13/2024 11:19:45 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 11:18:34 AM
- Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock • Business Wire • 05/13/2024 11:00:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/09/2024 10:40:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 10:25:46 PM
- Incyte to Present at Upcoming Investor Conference • Business Wire • 05/02/2024 12:00:00 PM
- Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs • Business Wire • 04/30/2024 11:00:00 AM
- Incyte annonce l'acquisition d'Escient Pharmaceuticals et de son portefeuille d'antagonistes MRGPR oraux premiers de leur catégorie • Business Wire • 04/23/2024 10:11:00 PM
- Incyte gibt Übernahme von Escient Pharmaceuticals und dessen Pipeline oraler First-in-Class-MRGPR-Antagonisten bekannt • Business Wire • 04/23/2024 10:01:00 PM
- Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists • Business Wire • 04/23/2024 11:00:00 AM
- Incyte to Report First Quarter Financial Results • Business Wire • 04/11/2024 12:00:00 PM
- Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia • Business Wire • 04/01/2024 12:30:00 PM
- Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/29/2024 08:30:00 PM
PickleJar Debuts Nationwide Contest With Brian Kelley for Fans to Win a Three-Day Bahama Cruise • NREG • Jun 3, 2024 8:45 AM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM